Chimeric Antibody CDR Segmentation for SARS-CoV-2 Spike Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and preventative measures for SARS-CoV-2 infections, such as convalescent plasma, are not universally effective, and there is a need for specific and effective antibodies or fragments that can bind to the SARS-CoV-2 spike protein or receptor binding domain to treat or prevent infections.
Innovation Solution
Development of chimeric antibodies and specific binding fragments comprising complementarity determining regions (CDRs) from antibodies like 4017-1B2, 4017-1D4, 4017-1H10, and 0002-2C4, which specifically bind to the SARS-CoV-2 spike protein or receptor binding domain, and their use in pharmaceutical compositions or diagnostic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If convalescent plasma is used as a treatment for SARS-CoV-2 infection, then some patients may show improvement, but the treatment is not universally effective
Solution Approach 1:
The patent segments the complex mixture of antibodies in convalescent plasma into specific monoclonal antibody candidates (4017-1B2, 4017-1D4, 4017-1H10, 0002-2C4) with defined CDR sequences. This segmentation allows for standardized production and consistent dosing, resolving the issue of variable effectiveness in plasma treatments while maintaining broad applicability through systematic evaluation of specific antibody candidates.
Solution Approach 2:
The patent changes the parameter of antibody specificity by selecting and characterizing monoclonal antibodies with specific CDR sequences that target the SARS-CoV-2 spike protein. This parameter change from polyclonal plasma to defined monoclonal antibodies enables standardized treatment protocols that can be universally applied, improving both reliability and adaptability.
2Measurement precision
If monoclonal antibodies with specific CDRs are developed to bind SARS-CoV-2 spike protein, then binding specificity is improved, but the complexity of antibody characterization and selection increases
Solution Approach 1:
The patent extracts and focuses on specific CDR sequences from the variable regions of monoclonal antibodies. By isolating only the critical CDR regions (residues 26-32, 50-56, and 91-96 of the heavy chain; and corresponding light chain regions), the complexity of characterizing entire antibodies is reduced while maintaining binding specificity. This extraction allows for simplified production and standardized characterization protocols.
Solution Approach 2:
The patent applies partial action by focusing characterization efforts on the critical CDR regions rather than analyzing the entire antibody molecule. This partial characterization approach provides sufficient information to define binding specificity and efficacy while significantly reducing the complexity and cost of antibody development and validation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies and fragments effectively bind to SARS-CoV-2 particles, potentially neutralizing the virus and aiding in diagnosis, offering a targeted approach to treating or preventing SARS-CoV-2 infections.
Implementation Method 1
the antibody or fragment specifically binds to an epitope expressed on a SARS-CoV-2 particle such as the spike protein or receptor binding domain
Data Source
AI summary
This disclosure relates to SARS-CoV-2 antibodies disclosed herein and specific binding fragments thereof, therapeutic and diagnostic uses, and compositions related thereto. In certain embodiments, this disclosure relates to antibodies disclosed herein and specific binding fragments thereof wherein the antibody or fragment specifically binds to an epitope expressed on a SARS-CoV-2 particle such as the spike protein or receptor binding domain. In certain embodiments, this disclosure relates to treating or preventing a SARS-CoV-2 or related coronavirus infection comprising administering an effective amount of an antibody disclosed herein or specific binding fragments thereof to a subject in need thereof.